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tients a lower body mass index and a decrease in body weight are
associated with worse outcome (4). Treatments that are clearly
beneficial in CHF have also been shown to prevent weight loss
(angiotensin-converting enzyme inhibitors and beta-blockers [4])
or even increased body fat mass (beta-blockers) (5). Until today
there are no data on changes in body weight or body composition
following CRT. We agree with Bax et al. (1) that much more
research remains to be done regarding CRT. We believe that
metabolic pathways should be an important focus of these inves-
tigations. This will promote our understanding of the pathophys-
iology of CHF and of the response to CRT and may help to better
guide patient selection for cardiac resynchronization therapy.
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REPLY
We thank Dr. Karhausen and colleagues for their constructive
comments concerning our manuscript of the unresolved issues in
cardiac resynchronization therapy (CRT) (1). As the researchers
point out, there are many such issues concerning CRT. The most
difficult issue remains the prediction of response to CRT (2). It has
become evident that the current selection criteria are not sufficient,
as 20% to 30% of patients do not respond to CRT. The most
promising techniques to better select the potential responders are
the different sophisticated tissue Doppler imaging (TDI) tech-
niques. However, as pointed out in part 1 of our review on CRT
(2), many techniques have been proposed. In total, 24 studies with
TDI to predict response to CRT have been published; only 2 (8%)
demonstrated that interventricular dyssynchrony was useful to
predict response, whereas all 24 studies demonstrated some value
of intraventricular (within the left ventricle) dyssynchrony for the
prediction of response to CRT. How to precisely assess the
intraventricular dyssynchrony is currently not clear, and the extent
of dyssynchrony (in ms) needed to result in response to CRT is
also uncertain.
Moreover, this uncertainty is further complicated by the fact
that a precise definition of a responder to CRT is lacking. As
emphasized by Dr. Karhausen and colleagues, various end points
have been used. In addition, a single patient may show improve-
ment in a certain end point, but not in another end point. This has
been highlighted recently by Bleeker et al. (3) showing a discrep-
ancy between improvement in clinical markers and echocardio-
graphic markers in patients undergoing CRT.
Finally, Dr. Karhausen and colleagues raise an even more
complicated issue, namely changes in metabolic status after CRT.
Indeed, this is a very important concern, and data on this topic are
virtually nonexistent. We fully agree with Dr. Karhausen and
colleagues that more work is needed, including in the field of
metabolic response to CRT.
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Allergic Reactions Following
Implantation of Drug-Eluting Stents:
A Manifestation of Kounis Syndrome?
In the very interesting study (1) and editorial (2) published in the
January 3, 2006 issue of the Journal, the investigators reported and
commented on 17 patients who developed allergic reactions after
implantation of drug-eluting stents (DES). These reactions in-
cluded rash, hives, itching, dyspnea, and fever. However, four
patients developed in-stent thrombosis and died at 4, 5, 18, and 18
months after implantation, respectively. Eosinophilia and elevated
immunoglobulin E (IgE) titers accompanied the allergic reactions.
One patient had implanted a TAXUS (Boston Scientific Corp.,
Natick, Massachusetts) stent impregnated with the antineoplastic
agent paclitaxel, and the other three had CYPHER (Cordis Corp.,
Miami Lakes, Florida) stents impregnated with the anti-
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inflammatory agent rapamycin. The other components of the
stents include the polymer coating and the metal stent itself. The
investigators concluded that hypersensitivity to DES is a real entity
that causes serious clinical sequelae, and they recommended
continuous vigilance and surveillance for any allergic reactions in
patients receiving DES.
The Kounis syndrome (3) was described 15 years ago as the
concurrence of acute coronary events with allergic or hypersensi-
tivity reactions as well as anaphylactic or anaphylactoid insults.
Arachidonic acid metabolites such as leukotrienes and thromboxane;
proteolytic enzymes such as chymase and tryptase; histamine and a
variety of cytokines and chemokines released during the activation
of various interrelated and interacting inflammatory cells such as
macrophages, T-lymphocytes, and mast cells have all been incrim-
inated to induce Kounis syndrome. Two variants of Kounis
syndrome have been described recently (4). The type I variant,
includes patients with normal coronary arteries and represents a
manifestation of endothelial dysfunction; the type II variant,
includes patients with culprit but quiescent preexisting atheroma-
tus disease. Causes of Kounis syndrome (5) include various
conditions, a variety of environmental exposures, and many drugs
such as antibiotics, contrast media, intravenous anesthetics, anal-
gesics, skin disinfectants, corticosteroids, thrombolytics, anti-
inflammatories, and antineoplastics. Antineoplastics capable of
inducing acute coronary syndrome (5) are the antimetabolite
5-fluorouracil (Adrucil, UpJohn Pharmaceuticals, Kalamazoo,
Michigan), its prodrug capecitabine (Xeloda, Roche Laboratories,
Nutley, New Jersey), the alkaloid cisplatin (Platinol, Bristol-Myers
Squibb, Princeton, New Jersey), the antimicrotubule paclitaxel
(Taxol, Bristol-Myers Squibb), the interleukin-2 agent denileukin
difitox (Ontak, Ligand Pharmaceuticals, San Diego, California),
the vinca alkaloids, and interferons.
All three components of DES could be responsible for inducing
allergic reactions and Kounis syndrome. Polymers, like those in
latex and vinyl gloves, have been reported to induce allergic
reactions and Kounis syndrome (6). Antineoplastics and anti-
inflammatory drugs can also induce Kounis syndrome (6). Patients
positive for allergic patch-test reactions to stent metal components
nickel and molybdenum appear to have increased rates of in-stent
thrombosis (7). The inflammatory cells found at autopsy to
infiltrate the intima, the media, and the adventitia in one of the
patients who died from in-stent thrombosis (8) were the same—
namely lymphocytes, plasma cells, macrophages, and eosinophils—
with those participating in the process of Kounis syndrome.
Indeed, the proportion of 262 cases of allergic reactions in 2
million DES insertions is very low, but it seems likely that some
cases might go unreported; thus, it is anticipated that many more
cases will be encountered in the coming years.
Responding, therefore, to the appeal of the RADAR (Research
on Adverse Drug events And Reports) project and until further
studies characterizing the incidence and the course of the reactions
and confirming or predicting the DES allergy are undertaken,
we recommend, especially in atopic individuals, the following:
1) careful history of adverse drug reactions and allergies in patients
receiving DES; 2) intradermal skin tests for every DES component
and desensitization strategies; 3) antibody testing including
enzyme-linked immunosorbent assay and radioallergosorbent test
for every DES component; 4) monitoring the levels of tryptase,
histamine, and arachidonic acid products immediately after the
allergic reaction appears; and 5) considering the use of cortico-
steroids and mast-cell stabilizers when the allergic reaction
appears. The latter have also abrogated late thrombotic events
experimentally (9).
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REPLY
We appreciate the letter by Dr. Kounis and colleagues that expands
upon our discussion of the literature on stent-associated hypersensi-
tivity (1). In conjunction with the RADAR (Research on Adverse
Drug events And Reports) project (2), we have started a protocol
that incorporates some of the suggestions of Dr. Kounis and
colleagues. This protocol includes skin tests to stent components
and laboratory tests. It also features a methodical approach to
dechallenge and rechallenge (3) for concomitant medication while
maintaining antiplatelet coverage. To refer patients, please contact
Dr. Marc Feldman, Associate Professor, Department of medicine,
University of Texas, San Antonio (E-mail: feldmanm@uthscsa.edu).
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